Important Inflammatory and Reactive Lesions of the Breast.

Some inflammatory and reactive lesions of the breast present problems clinically but are treated without resort to biopsy. In others, biopsy is required to make the correct diagnosis and to distinguish the process from malignancy. Still others represent incidental microscopic findings that may create diagnostic problems. This article reviews a number of inflammatory and reactive conditions that are likely to be encountered in routine surgical pathology practice, as well as those that have been recently described.

Pathologic features and immunophenotype of estrogen receptor-positive breast cancers in BRCA1 mutation carriers.

Although most breast cancers in BRCA1 mutation carriers are estrogen receptor negative (ER-) with a basal-like phenotype, up to one third are ER positive (ER+). Little is known about the characteristics of this subgroup. To address this, we compared histologic and immunophenotypic features of 60 BRCA1-related ER+ breast cancers with those of 85 BRCA1-related ER- cancers and 174 matched ER+ sporadic cancers. ER+ BRCA1-related cancers were significantly less likely than ER- BRCA1-related cancers to be of pure invasive ductal type (P<0.001) and to be of histologic grade 3 (P<0.001), and less frequently to have a high mitotic rate (P<0.001), pushing (or unknown) margins (P<0.001), a moderate/marked lymphocytic infiltrate (P=0.003), or geographic necrosis/fibrotic focus (P<0.001). In addition, ER+ BRCA1-related cancers less often expressed CK5/6 (P<0.0001), CK14 (P<0.0001), and epidermal growth factor receptor (P<0.0001) and more often expressed progesterone receptor (P<0.0001). In contrast, when compared with ER+ sporadic cancers, ER+ BRCA1-related cancers were significantly more often of invasive ductal type (P=0.005) and of histologic grade 3 (P=0.006), more frequently had a high mitotic rate (P=0.0003), and were more often CK14+ (P=0.03). On unsupervised cluster analysis, some ER+ BRCA1 cancers clustered more closely with sporadic ER+ cancers, whereas others clustered more closely with ER- BRCA1-related cancers. Nuclear expression levels of poly(ADP) ribose polymerase 1 in ER+ BRCA1-related cancers were similar to those in ER- BRCA1-related cancers but significantly higher than in ER+ sporadic cancers. We conclude that ER+ BRCA1-related breast cancers show several morphologic and immunophenotypic differences from ER+ sporadic breast cancers as well as some similarities to ER- BRCA1-related cancers.

Twenty-four-hour Bence-Jones protein determinations: can we ensure accuracy?

CONTEXT: Light chain disease represents 15% to 20% of cases of multiple myeloma. Current guidelines recommend monitoring these patients with 24-hour urine collections. OBJECTIVE: To determine the reliability of 24-hour urine collections in assessing the amount of Bence-Jones protein (BJP). DESIGN: We included all patients from our institution from 2003 through 2008 with BJP who had more than four 24-hour urine collections. We compared BJP excretion calculated from the submitted 24-hour collection with BJP excretion calculated by normalizing the collection to that patient's mean 24-hour creatinine excretion. We also looked at differences in serial values with these 2 methods. In addition, we evaluated the feasibility of using random urine samples to determine BJP excretion. RESULTS: A total of 14 patients with 135 24-hour urine collections met our inclusion criteria. The 24-hour urine creatinine excretion for each patient, which should be reasonably constant, varied considerably (coefficient of variation range 12%-30%). Differences in the 2 methods of calculating BJP excretion ranged from -1588 to 2315 mg/d. Among a total of 121 serial 24-hour measurements, the differences were clinically significant in 37 (30%). Among a total of 23 random urine samples from 11 of these patients submitted within 10 days of a 24-hour collection, the estimated BJP excretion appeared to be accurate in at least 18 (78%). CONCLUSIONS: Twenty-four-hour urine collections for BJP are, in practice, often misleading. At a minimum, one should verify that the 24-hour creatinine excretion is accurate. In addition, it may be possible to use the protein/creatinine ratio from random urine samples to determine 24-hour BJP excretion.